Tazobactam

CHEMBL404 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

300.3 g/mol

LogP

-2.0

Phase

4

This medication is a beta-lactamase inhibitor, meaning it protects antibiotics from being broken down by certain bacteria that have developed resistance. It is always combined with another antibiotic (such as piperacillin) rather than used alone, extending the antibiotic's ability to fight a broader range of serious infections. It is given intravenously in hospital settings for infections of the lungs, skin, urinary tract, and abdomen.

Molekularmasse

300,2900 g/mol

LogP

-2,00

TPSA

131,00 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Pancreatic Cancer Age-Related Macular Degeneration Hematology Pain Management Asthma Chronic Obstructive Pulmonary Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Oncology Chronic Kidney Disease Obesity Lymphoma Type 2 Diabetes Hypertension Chronic Pain Heart Failure Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O

InChI

InChI=1S/C10H12N4O5S/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h2-3,7-8H,4-5H2,1H3,(H,16,17)/t7-,8+,10+/m1/s1

Molecular Formula

C10H12N4O5S

HBD / HBA

1 / 7

Rotierbare Bindungen

3

Schwere Atome

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

This medication is a beta-lactamase inhibitor, meaning it protects antibiotics from being broken down by certain bacteria that have developed resistance. It is always combined with another antibiotic (such as piperacillin) rather than used alone, extending the antibiotic's ability to fight a broader range of serious infections. It is given intravenously in hospital settings for infections of the lungs, skin, urinary tract, and abdomen.

Yes, Tazobactam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL404. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 123630. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Tazobactam auf PillFYI

Struktur

Schnelldaten

Formel: C10H12N4O5S
Synonyme: 5

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.